ARWR
NASDAQArrowhead Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$79.89-0.90 (-1.11%)
01:30 PM07:45 PM
News · 26 weeks60-45%
2025-12-282026-06-21
Mix2690d
- Other13(50%)
- Insider5(19%)
- SEC Filings4(15%)
- Analyst2(8%)
- Earnings1(4%)
- Offering1(4%)
Latest news
25 items- PRArrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)REDEMPLO is the first and only authorised treatment for adults with FCS that does not require genetic confirmation of the conditionPeople living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, reducing their quality of lifeMarketing authorisation is supported by positive Phase 3 PALISADE study data, in which 25 mg REDEMPLO demonstrated an 80% reduction in triglycerides from baseline and an 83% reduction in the incidence of acute pancreatitis in a pooled analysis of patients using all doses of REDEMPLO compared with placeboArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that the European
- PRArrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D WebinarsArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced its plan to host a 2026 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company's proprietary Targeted RNAi Molecule (TRiM™) platform. Each webinar in the Summer Series will focus on a specific therapeutic area and will feature presentations by Arrowhead team members about the company's clinical candidates and external key opinion leaders, who will discuss the respective disease areas and treatment landscapes. Part I of Arrowhead's 2026 Summer Series of R&D Webinars will focus on Arrowhead's cardiometabolic pipeline and will be held on June 29, 2026,
- INSIDERDirector Cohen Matthew Gregory was granted 11,882 shares (SEC Form 4)4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
- INSIDERNew insider Cohen Matthew Gregory claimed no ownership of stock in the company (SEC Form 3)3 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
- SECArrowhead Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)
- PRArrowhead Pharmaceuticals to Participate in Upcoming June 2026 EventsArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming events: 2026 Jefferies Global Healthcare Conference – June 2-4, 2026 Type: Fireside Chat Presentation Date/Time: June 3, 2026, 8:10 am EDT Goldman Sachs 47th Annual Global Healthcare Conference – June 8-10, 2026 Type: Fireside Chat Presentation Date/Time: June 10, 2026, 9:00 am EDT Presentation materials and webcast links, if applicable, may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website. About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals (NASDAQ:ARWR) is a commercial-stage pharmaceutical compa
- PRArrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026- Targeting Activin E may represent a novel therapeutic strategy for metabolic dysfunction-associated steatohepatitis (MASH) and obesity‑related metabolic dysfunction - ARO-INHBE produced meaningful reductions in liver fat content as a monotherapy or in combination with low-dose tirzepatide in individuals with obesity with or without Type 2 Diabetes Mellitus (T2DM) - Longer exposure to ARO-INHBE silencing resulted in continued improvements in visceral fat and liver fat from Week 12 to Week 24 Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today presented interim results from a Phase 1/2a clinical trial of ARO-INHBE, the company's investigational RNA interference (RNAi) therapeutic bein
- PRArrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress- New data support potential use of plozasiran without dose adjustment in patients with moderate-to-severe renal or moderate hepatic impairment - Case report suggests that preconception exposure to plozasiran may be associated with sustained lowering of fasting triglyceride levels throughout the term of a pregnancy Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today presented new positive clinical data for plozasiran supporting its use in patients with moderate-to-severe renal impairment or moderate hepatic impairment without the need for dose adjustment, and a case report suggesting that preconception exposure to plozasiran may be associated with sustained lowering of fasting triglycer
- INSIDERDirector Lu Hongbo sold $228,334 worth of shares (2,970 units at $76.88) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 52,012 units (SEC Form 4)4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
- PRWall Street's Cardiac Bet: Where Diagnostics Meet the MoneyISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.USANewsGroup.com News CommentaryVANCOUVER, BC, May 12, 2026 /CNW/ -- Cardiovascular disease is about to become the most expensive problem in American medicine. The American Heart Association fired a warning shot in late April: U.S. heart disease costs are on pace to quadruple by 2050, and total national healthcare spending is already closing in on $5 trillion a year[1]. That kind of structural pressure is forcing hospitals to rethink how they diagnose and treat cardiac patients, and the money is following. The global AI cardiology market, valued at $2.78 billion this year, is projected to reach over $14 billion by 2034 as health systems race to
- SECSEC Form S-8 filed by Arrowhead Pharmaceuticals Inc.S-8 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)
- SECSEC Form 10-Q filed by Arrowhead Pharmaceuticals Inc.10-Q - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)
- SECArrowhead Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)
- PRArrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results- Conference Call and Webcast Today, May 7, 2026, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026. The Company is hosting a conference call today, May 7, 2026, at 4:30 p.m. ET to discuss the results. "Arrowhead continues to show strong execution in meeting and exceeding our commercial, R&D, and corporate goals. The company is on extremely strong footing to continue to drive growth in the near-term with numerous opportunities to create long-term shareholder value," said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. "We remain focused on a few key areas as
- SECSEC Form SCHEDULE 13G filed by Arrowhead Pharmaceuticals Inc.SCHEDULE 13G - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)
- PRArrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals- Precision approach targets patients who have a mutation in the PNPLA3 gene, which is highly prevalent among Hispanic patients with MASH - Phase 1 data published in The New England Journal of Medicine demonstrated a 46% reduction in liver fat in homozygous patients and a well-tolerated safety profile Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (NASDAQ:MDGL) for ARO-PNPLA3, Arrowhead's clinical stage RNA interference (RNAi) therapeutic designed to reduce liver expression of patatin-like phospholipase domain containing 3 (PNPLA3) as a potential treatment for patients with metabolic dysfunction-associ
- PRArrowhead Pharmaceuticals to Participate in Upcoming May 2026 EventsArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming events: BofA Securities 2026 Healthcare Conference – May 12-14, 2026 Type: Investor Group Dinner Date/Time: May 12, 2026 Type: Fireside Chat Presentation Date/Time: May 13, 2026, 10:00 am PDT TIDES USA Oligonucleotide & Peptide Therapeutics – May 11-14 in Boston, Massachusetts Title: Systemic RNAi Targeting MAPT: Advancing Tau Suppression Across the CNS with TRiM™ SC Date/Time: May 13, 2026, 4:45 PM EDT Presenter: Kayal Madhivanan 33rd European Congress on Obesity (ECO 2026) – May 12-15 in Istanbul, Türkiye Title: Elevated Activin E levels correlate with
- ANALYSTAnalyst initiated coverage on Arrowhead with a new price targetAnalyst initiated coverage of Arrowhead with a rating of Overweight and set a new price target of $88.00
- PRArrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)– REDEMPLO is the first and only medicine approved for use in the treatment of FCS in Australia, and is authorized for both genetically confirmed and clinically diagnosed adult patients with FCS – People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, often resulting in a reduced quality of life – The approval in Australia is based on positive results from the Phase 3 PALISADE study where REDEMPLO reduced triglycerides by a median of 80% from baseline and significantly reduced the incidence of acute pancreatitis across pooled doses, as compared with those using placebo Arrowhead Pharmace
- INSIDERChief Financial Officer Apel Daniel Joseph sold $934,285 worth of shares (13,095 units at $71.35) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 162,905 units (SEC Form 4) (withholding obligation)4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
- INSIDERChief Medical Officer Hamilton James C sold $750,000 worth of shares (10,000 units at $75.00) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 226,958 units (SEC Form 4)4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
- PRArrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe– If confirmed by the European Commission, REDEMPLO would be the first and only siRNA medicine authorized in the EU for both genetically confirmed and clinically diagnosed adult patients with FCS – People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, often resulting in a reduced quality of life – The CHMP opinion is based on positive results from the Phase 3 PALISADE study where REDEMPLO reduced triglycerides by a median of 80% from baseline and significantly fewer cases of acute pancreatitis were seen in patients using REDEMPLO compared with those using placebo Arrowhead Pharmaceutica
- ANALYSTArrowhead upgraded by Morgan Stanley with a new price targetMorgan Stanley upgraded Arrowhead from Equal-Weight to Overweight and set a new price target of $100.00
- PRArrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter ResultsArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on May 7, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 second quarter ended March 31, 2026. Webcast and Conference Call Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register-conf.media-server.com/register/BI94a3f6754bd3471e8e895704fb645ee5. Once registered, you will r
- PRArrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo– Patients with severe hypertriglyceridemia (sHTG) achieved an 83% median reduction in triglycerides (TG), with 96% of patients achieving TG levels below 500 mg/dL, a threshold associated with increased risk of acute pancreatitis – No adjudicated acute pancreatitis events occurred in any patient receiving plozasiran during the 2-year Phase 2b Open-Label Expansion (OLE) Study – Favorable and durable improvements in atherogenic lipoproteins, including remnant cholesterol, non-HDL cholesterol, and ApoB, were observed, with a safety profile consistent with earlier trials Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced long-term efficacy and safety data from a two-year long o
ARWR FAQ
6 questionsWhat does Arrowhead Pharmaceuticals Inc. do?
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC...Where does ARWR stock trade?
Arrowhead Pharmaceuticals Inc. (ARWR) is listed on NASDAQ.What sector and industry is ARWR in?
Arrowhead Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ARWR?
Arrowhead Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Overweight on 2026-05-01. Recent price targets range from $2900.00 to $4000.00.What companies are similar to ARWR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ARWR side-by-side with any of them on Quantisnow.How can I track ARWR on Quantisnow?
Quantisnow aggregates Arrowhead Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARWR to receive live email and push alerts on every new disclosure.